Nasdaq: **OKYO**

Market Data

OKYO Pharma Ltd.
Nasdaq: **OKYO**

Fiscal Year	Dec. 31
Price	$1.04
Market Cap	$35.2M
Shares Out.	33.8M
Float	24.5M
Avg. Vol. (90-day)	41,999
Cash (mrq)[1]	$0.8M

Price & share data as of August 22, 2024

Auditor:
Forvis Mazars LLP

Legal Counsel:
Orrick, Herrington & Sutcliffe (UK) LLP

Transfer Agent:
Worldwide Stock Transfer, LLC

okyopharma.com

Company Overview

OKYO Pharma a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy. Leveraging a unique lipid-conjugated chemerin peptide, OKYO's lead candidate, OK-101, is designed to address inflammation and pain more effectively than current treatments. The recent Phase 2 trial for DED demonstrated notable improvements in both symptoms and signs within just 15 days, with a favorable safety profile and no drug-related serious adverse events. Moreover, OK-101 also offers a significant opportunity to treat the ocular disease called NCP, with no FDA approved drug to treat patients suffering from this acute, chronic, ocular condition. OKYO's robust patent protection through at least 2039, plus an experienced management team, with proven success in clinical development thru FDA approval, underscore its strong positioning for future growth in ophthalmology therapeutics.

Investment Highlights

Innovative pipeline targeting large, underserved markets with high unmet medical needs

- Lead candidate, OK-101, a novel lipid-conjugated chemerin peptide, targets two significant ocular conditions: Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP)
- DED is a multi-billion-dollar market with over 38 million affected individuals in the U.S. alone
- NCP represents an untapped market with no current FDA-approved treatments, offering substantial growth potential for OKYO
- Recent Phase 2 trial for OK-101 in DED showed significant improvements in both symptoms and signs as early as 15 days, with a strong safety profile and no drug-related serious adverse events
- Expect to launch Phase 2 trial for NCP in 3Q24

Strong intellectual property

- Patents provide protections through at least 2039 with potential extensions further enhancing competitive position

Experienced leadership with proven track record

- Extensive experience in drug development with history of successful drug commercialization
- CEO co-founded Synergy Pharmaceuticals and was instrumental in developing and securing FDA approval for Trulance®, a drug now marketed by Bausch Health
- CSO brings 30+ years of ophthalmic research and pharmaceutical R&D experience; authored 50+ peer-reviewed publications

Nasdaq: **OKYO**

38,000,000 US DED patients**

18,000,000 Diagnosed**

1,200,000 Treated for DED**

* Craig JP et al. Ocul Surf. 2017; 15:276; **Market Scope 2023 Dry Eye Product Market Review; does not include OTC artificial tears and other Rx anti-inflammatory and tear stimulants

Value Proposition

OKYO is advancing its lead candidate, OK-101, a novel lipid-conjugated chemerin peptide, which targets both Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), two significant areas of unmet medical need.

The recent Phase 2 trial for DED demonstrated rapid and notable improvements in symptoms and signs within just 15 days, coupled with a strong safety profile and no drug-related serious adverse events. With over 38 million people affected by DED in the U.S. alone, OK-101 could capture a substantial share of this multi-billion-dollar market upon approval. Additionally, the potential to address NCP, a condition with no FDA-approved therapies, opens a new market opportunity with significant growth potential. OKYO's robust intellectual property portfolio, which extends through at least 2039, further strengthens its competitive advantage.

The company is led by an experienced management team, with CEO Dr. Gary S. Jacob, who has over 35 years in the biopharma industry and has successfully guided a drug through FDA approval, and CSO Dr. Raj Patil, who brings 30 years of ophthalmic research expertise. Looking ahead, OKYO plans to initiate a Phase 2 trial for NCP in Q3 2024, providing multiple near-term catalysts for investors. This combination of a differentiated product candidate, significant market opportunities, and experienced leadership makes OKYO Pharma a compelling investment opportunity in the ophthalmology therapeutics space.

Pipeline

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
OK-101				
Dry Eye Disease ("DED")	Phase 2 Trial Completed			
Neuropathic Corneal Pain ("NCP")	Plan to open trial in Q3 2024			
Allergic Conjunctivitis				
Uveitis				